Associated Genetic Biomarkers
Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (IKBKE) is a gene that encodes a protein kinase that regulates antiviral signaling pathways. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
IKBKE is altered in 1.20% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, and breast invasive lobular carcinoma having the greatest prevalence of alterations .
The most common alterations in IKBKE are IKBKE Mutation (0.50%), IKBKE Amplification (0.37%), IKBKE Loss (0.02%), IKBKE V365I (0.01%), and IKBKE R117C (0.01%) .
IKBKE status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains IKBKE status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with IKBKE status in the inclusion eligibility criteria most commonly target bladder carcinoma and urothelial carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is IKBKE Mutation .
Olaparib is the most frequent therapy in trials with IKBKE as an inclusion criteria .
Significance of IKBKE in Diseases
Bladder Carcinoma +
Urothelial Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.